CAR T-cell Therapy Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global CAR T-cell therapy market growth forecasted to transform from USD 5.5 billion in 2024 to USD 29.0 billion by 2029, driven by a CAGR of 39.6%. The growth of this market due to the rise in investments and funding for CAR T-cell therapy developments and technological advancements in CAR T-cell therapy. The growing prevalence of cancer is also expected to support lucrative market growth. However, the high costs of CAR T-cell therapies and the adverse effects of the drugs are some of the factors likely to hamper the market growth.

CAR T-cell Therapy Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Global CAR T-cell therapy market Dynamics

Driver: Growing cancer prevalence

The growing prevalence of cancer is a prominent driver of market growth. According to the World Health Organization, in 2022, there were ~20 million new cancer cases and 9.7 million cancer-related deaths globally. An estimated 53.5 million individuals were living within five years of a cancer diagnosis. Statistically, about one-fifth of people will develop cancer in their lifetime, with approximately 1 in 9 men and 1 in 12 women succumbing to the disease. A projected surge of over 35 million new cancer cases is anticipated by 2050, reflecting a substantial 77% increase from the estimated 20 million cases recorded in 2022. Of these, Diffuse Large B-Cell Lymphoma (DLBCL) is the predominant form of Non-Hodgkin Lymphoma (NHL) in the US and globally, representing ~22% of newly identified cases of B-cell NHL in the US. Each year, over 18,000 individuals receive a diagnosis of DLBCL.

Restraint: High therapy costs

The high cost of CAR T-cell therapy represents a significant restraint on the market, posing challenges to widespread adoption and accessibility. One of the primary factors contributing to the elevated cost is the complex and individualized manufacturing process required for CAR T-cell therapies. Each treatment involves extracting T cells from the patient, genetically modifying them to express chimeric antigen receptors (CARs), and expanding these cells in a controlled laboratory environment before reinfusing them into the patient. This labor-intensive and time-consuming process incurs substantial costs, often exceeding USD 350,000 per treatment, as seen with therapies like KYMRIAH and Yescarta.

Opportunity: Expansion into solid tumors

Expansion into solid tumors represents a significant opportunity for the CAR T-cell therapy market, offering the potential for market growth and therapeutic advancements. Traditionally, CAR T-cell therapies have successfully treated hematologic malignancies such as B-cell lymphomas and Acute Lymphoblastic Leukemia (ALL). However, the application of CAR T-cell therapies to solid tumors has been limited due to unique challenges such as the hostile tumor microenvironment, heterogeneity, and physical barriers within solid tumors. Advances in this area can unlock new avenues for growth and innovation in the market.

Challenge: Patient recruitment for trials

Patient recruitment for clinical trials is a significant challenge in the CAR T-cell therapy market, posing obstacles to developing and approving new therapies. The complexity of CAR T-cell therapy trials, stringent eligibility criteria, and the rarity of target indications all contribute to the difficulty of enrolling sufficient patient numbers. One primary challenge is the stringent eligibility criteria for CAR T-cell trials. These criteria often include specific genetic markers, disease subtypes, and previous treatment histories, significantly narrowing the pool of eligible participants. Moreover, the geographic dispersion of patients with rare cancers adds complexity to patient recruitment. Rare conditions such as certain types of Acute Lymphoblastic Leukemia (ALL) or relapsed large B-cell Lymphoma have a limited patient base scattered across wide regions. This dispersion complicates the logistics of enrolling and managing patients in clinical trials.

Ecosystem Analysis Car T-Cell Therapy Manufacturing Market

The product CAR T-cell therapy segment of the Car T-Cell Therapy Manufacturing Industry commanded market share in 2023.

Based on the products, the CAR T-cell therapy market is segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. The Yescarta segment accounted for the largest share of the CAR T-cell therapy market in 2023. The high share of this segment is mainly attributed to the early entry into the market allowing Gilead Sciences, Inc. to gain significant experience in commercialization and market dynamics and establish a strong brand presence. Additionally, advancements in Yescarta is further likely to drive segmental growth. For example, Gilead Sciences, Inc. received U.S. FDA approval for a change in the manufacturing process for Yescarta which would result in reduced median turnaround time from leukapheresis to product release from 16 Days to 14 Days.

The CD19 target antigen segment of the CAR T-cell therapy industry is poised to exhibit substantial growth at a significant CAGR throughout the forecast period.

Based on targets, the CAR T-cell therapy market is classified into segmented into BCMA, CD19 and other targets. In 2023, the CD19 targets segment accounted for the highest share of the global CAR T-cell therapy market. The large share of this segment is due to the to the growing prevalence of cancers such as B-cell Lymphomas which express CD19 antigen on the cell surface.

Asia Pacific region of the CAR T-cell therapy industry is estimated to exhibit highest CAGR during the forecast period of 2024-2029.

There are five main regional segmentations for the CAR T-cell therapy market—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2023, North America held dominant share in CAR T-cell therapy market. Early adoption & regulatory framework, significant investment in research and development and advanced healthcare infrastructure are some of the factors uplifting the market growth in the region. Asia Pacific is anticipated to grow at significant CAGR during the forecast period of 2024-2029. Increasing healthcare investments, rising cancer incidence, rich CAR T-cell therapy pipeline development, and supportive regulatory frameworks are likely to drive the growth of the CAR T-cell therapy market in the region.

Source: Expert Interviews, Secondary Research, Whitepapers, Journals, Magazines, and MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Key players in the Market include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), CARsgen Therapeutics Holdings Limited (China), IASO Biotherapeutics (China), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), CRISPR Therapeutics (Switzerland), Autolus Therapeutics (UK), Allogene Therapeutics (US), Cartesian Therapeutics, Inc. (US), Guangzhou Bio-gene Technology Co., Ltd (China) and Wugen (US).

Scope of the CAR T-cell Therapy Industry:

This report categorizes the CAR T-cell therapy market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• ABECMA
• BREYANZI
• CARVYKTI
• YESCARTA
• TECARTUS
• KYMRIAH
• Other Products

By Target

• CD19
• BCMA
• Other Targets

By Indication

• Multiple Myeloma
• B-Cell Lymphoma (BCL)
• Acute Lymphoblastic Leukemia (ALL)
• Other Indications

By Demographic

• Adult
• Pediatric

By End User

• Hospitals
• Long Term Care Facilities
• Specialty Centres

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa

Recent Developments of CAR T-cell Therapy Industry:

• In May 2024, The US FDA granted accelerated approval to BREYANZI (lisocabtagene maraleucel) for the treatment of adult patients with relapsed or refractory Follicular Lymphoma (FL) who have received two or more prior lines of systemic therapy.
• In April 2024, Bristol entered into a worldwide capacity reservation and supply agreement with Cellares to manufacture CAR T-cell therapies using Cellares’s automated & high-throughput manufacturing platform called Cell Shuttle.
• In January 2023, Gilead received approval from the US FDA for a change in manufacturing processes for YESCARTA (axicabtagene ciloleucel) to reduce the median turnaround time (TAT) in the US to 14 days from 16 days.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst